Literature DB >> 17043926

Memantine fails to facilitate partial cigarette deprivation in smokers--no role of Memantine in the treatment of nicotine dependency?

N Thuerauf1, J Lunkenheimer, B Lunkenheimer, W Sperling, S Bleich, M Schlabeck, J Wiltfang, J Kornhuber.   

Abstract

The efficacy of Memantine in the treatment of nicotine dependency in humans remained to be evaluated. The aims of our pilot study were to investigate (1) the effectiveness of Memantine in facilitating smoking reduction and (2) the influence of Memantine on the perception of nicotine. In order to achieve these aims we conducted a placebo controlled double-blind parallel group study in smokers (n = 20 per group). Before the beginning of the treatment-phase (10/20 mg Memantine per day) all participants were instructed to reduce smoking (partial deprivation). Before and during partial deprivation we registered the daily cigarette consumption and craving estimates. Following nasal stimulation with nicotine enantiomers hedonic and intensity estimates and the discrimination ability were assessed. Memantine failed to facilitate smoking reduction and did not influence the perception of nicotine with the exception of a weak reduction of olfactory intensity estimates reaching statistical significance for one nicotine enantiomer only.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17043926     DOI: 10.1007/s00702-006-0570-y

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  48 in total

1.  Enrichment induces structural changes and recovery from nonspatial memory deficits in CA1 NMDAR1-knockout mice.

Authors:  C Rampon; Y P Tang; J Goodhouse; E Shimizu; M Kyin; J Z Tsien
Journal:  Nat Neurosci       Date:  2000-03       Impact factor: 24.884

2.  Effects of the non-competitive NMDA-receptor antagonist memantine on morphine- and cocaine-induced potentiation of lateral hypothalamic brain stimulation reward.

Authors:  T M Tzchentke; W J Schmidt
Journal:  Psychopharmacology (Berl)       Date:  2000-04       Impact factor: 4.530

3.  MK801 attenuates behavioural adaptation to chronic nicotine administration in rats.

Authors:  M Shoaib; I P Stolerman
Journal:  Br J Pharmacol       Date:  1992-03       Impact factor: 8.739

4.  Dose-related ethanol-like effects of the NMDA antagonist, ketamine, in recently detoxified alcoholics.

Authors:  J H Krystal; I L Petrakis; E Webb; N L Cooney; L P Karper; S Namanworth; P Stetson; L A Trevisan; D S Charney
Journal:  Arch Gen Psychiatry       Date:  1998-04

5.  Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs.

Authors:  F E Pontieri; G Tanda; F Orzi; G Di Chiara
Journal:  Nature       Date:  1996-07-18       Impact factor: 49.962

6.  Right-nostril advantage for discrimination of odors.

Authors:  R J Zatorre; M Jones-Gotman
Journal:  Percept Psychophys       Date:  1990-06

Review 7.  Presynaptic dopaminergic modulation of cortical input to the striatum.

Authors:  J Kornhuber; M E Kornhuber
Journal:  Life Sci       Date:  1986-08-25       Impact factor: 5.037

8.  Ethanol-like discriminative stimulus effects of non-competitive n-methyl-d-aspartate antagonists.

Authors:  K.A. Grant; J.S. Knisely; B. Tabakoff; J.E. Barrett; R.L. Balster
Journal:  Behav Pharmacol       Date:  1991-04       Impact factor: 2.293

9.  Multicenter investigation of 1,036 subjects using a standardized method for the assessment of olfactory function combining tests of odor identification, odor discrimination, and olfactory thresholds.

Authors:  G Kobal; L Klimek; M Wolfensberger; H Gudziol; A Temmel; C M Owen; H Seeber; E Pauli; T Hummel
Journal:  Eur Arch Otorhinolaryngol       Date:  2000       Impact factor: 2.503

10.  The NMDA antagonist memantine blocks the expression and maintenance of morphine dependence.

Authors:  P Popik; P Skolnick
Journal:  Pharmacol Biochem Behav       Date:  1996-04       Impact factor: 3.533

View more
  11 in total

1.  Chronic memantine decreases nicotine self-administration in rats.

Authors:  Edward D Levin; Corinne Wells; Leah Yao; Wendi Guo; Anica Nangia; Sarah Howard; Erica Pippen; Andrew B Hawkey; Jed E Rose; Amir H Rezvani
Journal:  Eur J Pharmacol       Date:  2019-08-14       Impact factor: 4.432

2.  Physiological effects of cigarette smoking in the limbic system revealed by 3 tesla magnetic resonance spectroscopy.

Authors:  Angelika Mennecke; Andrea Gossler; Thilo Hammen; Arnd Dörfler; Andreas Stadlbauer; Julie Rösch; Johannes Kornhuber; Stefan Bleich; Marc Dölken; Norbert Thürauf
Journal:  J Neural Transm (Vienna)       Date:  2014-03-19       Impact factor: 3.575

Review 3.  Do specific NMDA receptor subunits act as gateways for addictive behaviors?

Authors:  F W Hopf
Journal:  Genes Brain Behav       Date:  2016-11-18       Impact factor: 3.449

Review 4.  The role of memantine in the treatment of psychiatric disorders other than the dementias: a review of current preclinical and clinical evidence.

Authors:  Gabriele Sani; Giulia Serra; Giorgio D Kotzalidis; Silvia Romano; Stefano M Tamorri; Giovanni Manfredi; Matteo Caloro; C Ludovica Telesforo; Saverio S Caltagirone; Isabella Panaccione; Alessio Simonetti; Francesca Demontis; Gino Serra; Paolo Girardi
Journal:  CNS Drugs       Date:  2012-08-01       Impact factor: 5.749

Review 5.  Role of the glutamatergic system in nicotine dependence : implications for the discovery and development of new pharmacological smoking cessation therapies.

Authors:  Matthias E Liechti; Athina Markou
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

Review 6.  Mechanism-based medication development for the treatment of nicotine dependence.

Authors:  Zheng-xiong Xi; Krista Spiller; Eliot L Gardner
Journal:  Acta Pharmacol Sin       Date:  2009-05-11       Impact factor: 6.150

7.  Smoking reduction interventions for smoking cessation.

Authors:  Nicola Lindson; Elias Klemperer; Bosun Hong; José M Ordóñez-Mena; Paul Aveyard
Journal:  Cochrane Database Syst Rev       Date:  2019-09-30

Review 8.  Memantine: a review of studies into its safety and efficacy in treating Alzheimer's disease and other dementias.

Authors:  Stuart J Thomas; George T Grossberg
Journal:  Clin Interv Aging       Date:  2009-10-12       Impact factor: 4.458

Review 9.  New Pharmacological Agents to Aid Smoking Cessation and Tobacco Harm Reduction: What Has Been Investigated, and What Is in the Pipeline?

Authors:  Emma Beard; Lion Shahab; Damian M Cummings; Susan Michie; Robert West
Journal:  CNS Drugs       Date:  2016-10       Impact factor: 5.749

10.  Effects of topiramate on cue-induced cigarette craving and the response to a smoked cigarette in briefly abstinent smokers.

Authors:  Malcolm S Reid; Joseph Palamar; Sumithra Raghavan; Frank Flammino
Journal:  Psychopharmacology (Berl)       Date:  2007-03-08       Impact factor: 4.415

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.